Amani Therapeutics Raises $25M for Schizophrenia Drug

Amani Therapeutics has successfully closed a $25 million Series A funding round, injecting significant capital to propel its innovative treatment for serious neuropsychiatric disorders toward advanced clinical stages. The financing was spearheaded by healthcare-focused investment firm RTW Investments, LP.

The core of Amani's development efforts centers on AM-01, a unique fixed-dose combination therapy. This candidate pairs the established antipsychotic clozapine with a novel chemical entity (NCE) for which Amani has secured global rights from AstraZeneca. The strategic aim is to create a best-in-class option for individuals suffering from treatment-resistant schizophrenia.

A significant hurdle in utilizing clozapine, the sole FDA-approved medication for treatment-resistant schizophrenia, is the risk of neutropenia, a severe reduction in white blood cells. This side effect necessitates rigorous and frequent blood monitoring, a burden that limits its prescription to fewer than 5% of eligible patients in the U.S., despite its proven efficacy. The market for treatment-resistant schizophrenia is substantial, affecting an estimated 2.6 million adults in the United States, with a considerable segment facing limited therapeutic options.

AM-01 is engineered to directly address this critical unmet need by mitigating clozapine-induced neutropenia. By potentially easing the stringent monitoring requirements, Amani Therapeutics seeks to broaden access to clozapine's therapeutic benefits for a patient population currently underserved. This advancement could fundamentally alter the treatment paradigm for a condition with profound societal and individual impact.

Complementing the financial infusion, Amani Therapeutics has bolstered its executive leadership. Rob Swoboda joins as Chief Operating Officer, bringing extensive experience from previous roles at Karuna Therapeutics, bluebird bio, and Vertex Pharmaceuticals. Additionally, Dr. Carla Canuso has been appointed Chief Medical Officer, arriving from Johnson & Johnson, where she led neuropsychiatry efforts. Their combined expertise is expected to guide AM-01 through its developmental milestones.

The company's scientific premise, as articulated by Dr. Canuso, is grounded in a deeper understanding of the mechanisms underlying clozapine-induced neutropenia. Amani believes its approach offers a viable solution to enhance patient outcomes and improve the overall treatment experience for those with severe neuropsychiatric conditions. The successful Series A positions Amani Therapeutics to make a significant impact in a therapeutic area ripe for innovation.